MediciNova Inc (NASDAQ:MNOV)
| 1.82 Delayed Data As of Nov 29 |  -0.01 / -0.54%Today’s Change | 1.71 Today|||52-Week Range 2.73 | -11.22% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $88.8M |
Company Description
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
Contact Information
MediciNova, Inc. 4275 Executive Square La Jolla California 92037 |
Employees
Shareholders
| Individual stakeholders | 22.36% |
| Mutual fund holders | 2.92% |
| Other institutional | 16.30% |
Top Executives
| Yuichi Iwaki | President, Chief Executive Officer & Director |
| Jason Kruger | Chief Financial Officer |
| Kazuko Matsuda | Director & Chief Medical Officer |
| Geoffrey G. O'Brien | Vice President & Executive Officer |
| David H. Crean | Chief Business Officer |
